Nephrogenic Diabetes Insipidus Clinical Trial
Official title:
Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus
Verified date | February 2018 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to determine if two investigational medications will be more effective in decreasing urine output than the currently available and routinely used medications in patients with congenital nephrogenic diabetes insipidus (NDI).
Status | Completed |
Enrollment | 4 |
Est. completion date | October 2012 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 5 Years to 25 Years |
Eligibility |
Inclusion Criteria: - Known diagnosis of Congenital Nephrogenic Diabetes Insipidus (CNDI) - Age 5 to 25 years - Normal kidney function - Post-void residual urine < 200 ml (determined by bladder ultrasound) Exclusion Criteria: - Impaired kidney function - Known urinary retention or bladder dysfunction - High blood pressure - Other significant chronic medical disease (e.g., heart failure, liver disease, etc.) - Allergy to study drugs |
Country | Name | City | State |
---|---|---|---|
Denmark | University of Aarhus | Aarhus | |
United States | University of Colorado at Denver and Health Sciences Center | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | University of Aarhus |
United States, Denmark,
Bichet DG. Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis. 2006 Apr;13(2):96-104. Review. — View Citation
Bouley R, Pastor-Soler N, Cohen O, McLaughlin M, Breton S, Brown D. Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am J Physiol Renal Physiol. 2005 Jun;288(6):F1103-12. Epub 2005 Jan 11. — View Citation
Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. Review. — View Citation
Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frøkiaer J, Nielsen S. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. — View Citation
Nielsen S, Frøkiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002 Jan;82(1):205-44. Review. — View Citation
Nielsen S, Kwon TH, Frøkiaer J, Agre P. Regulation and dysregulation of aquaporins in water balance disorders. J Intern Med. 2007 Jan;261(1):53-64. Review. — View Citation
Schrier RW, Cadnapaphornchai MA, Umenishi F. Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonists. Heart Dis. 2001 May-Jun;3(3):210-4. Review. — View Citation
Schrier RW, Cadnapaphornchai MA. Renal aquaporin water channels: from molecules to human disease. Prog Biophys Mol Biol. 2003 Feb;81(2):117-31. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 24h Urine Volume | urine volume in mL/d | 4-days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05190744 -
PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
|
Phase 2 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Completed |
NCT04939753 -
Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective Analysis
|
||
Not yet recruiting |
NCT05307042 -
Decline in Renal Concentration Ability in Lithium Treated Patients
|